Dr.Prashant Jani

Dr.Prashant A.Jani.

Email : dr.prashant.jani@gmail.com

Web  www.oncopathology.blogspot.ca

 Dr. Prashant Jani completed his MBBS (1994) and MD (1997) from Pune University, India. He then migrated to Canada and completed a residency in Anatomic Pathology, and FRCPC, from the University of Toronto, Ontario, Canada (2001-2005). He currently works as an Anatomic Pathologist Thunder Bay Regional Health sciences Centre and Northern Ontario Cancer Research Centre, Thunder Bay, Ontario, Canada. He also is the Associate Professor, Northern Ontario School of Medicine, Ontario, Canada. He has also been on the faculty on the Cancer Pathology Course, in Thunder Bay, Ontario. He is a dynamic pathologist with more than 15 years of experience. His special interest is Oncopathology. He is founder of International society of Oncopathology.He continues to visit Pune every year, conducting a International Oncopathology CME in Jan of each year, which is very well attended by 350  Pathologists from all over India. He is also founder of International reference center for cancer Pathology- OncoPath Diagnostics, India. This is India's first International reference center with Digital scanning system.The center provides international consultation to the patients in India- at  no extra cost !!!

He is active 
member of  United states and Canadian Academy of Pathology meetings, and has many platform presentations and posters to his credit. He has  published many papers in international journals.

Dr.Jani has been awarded Lorraine Dougal  award by Association of Indian Pathologists in North America for his outstanding contribution to Pathology services in India.

2001-2005-     FRCPC
                        Anatomic Pathology Residency,
University of Toronto, Ontario, Canada.
1994-1997 -    M.D.
                       General pathology,  
University of Pune, India 
1987-1994 –    M.B.B.S. 
 University of Pune, India 
 April 2009- Fellow of College of American Pathologist  (FCAP)

  • Aug.2005 – Current date
    • Anatomic Pathologist, Thunder Bay Regional Health sciences Centre and  Northern Ontario Cancer Research Centre, Thunder Bay, Ontario, Canada.
    • Associate Professor, Department of Pathology and Laboratory medicine. Northern Ontario School of Medicine. Ontario, Canada.
  • 03/2001- 05/2005- Resident, Anatomic Pathology, University of  Toronto, Canada
  • 01/1997 – 1/2001-Private Consultant Pathologist,  Pune India 
  • 01/1997 –01/2001-Cytopathologist, Care India Medical Society Pune, India
  • 06/1997 –02/1998-Cytopathologist, B.J. Medical College, Pune, India. 
  • 01/1994 –12/1997-Blood Transfusion Officer, Red Cross Blood Bank, Pune,India.

1)    D-240 expression on luminal surface of pulmonary   airspaces in normal developing and adult lung but is lost in conditions associated with intra alveolar infiltrates.

  • Presentation at Unites states and Canadian Academy of Pathology,2005, San Antanio, USA


2)   Aberrant expression of CD4 and CD7 T cell antigens in   Atypical B cell –

      Chronic  Lymphocytic leukemia.

  • Presentation at American Society of Clinical Pathology, Nov.2005, Chicago, USA.
  • Prashant Jani,Abdel Walkett and Hong Chang,Am J Hematol.2007 Jan;82(1):73-6.


3)   CD 138 expression in Merkel cell carcinoma: A potential diagnostic pitfall in hematological malignancies.

  • Presentation at  Annual meeting of Canadian Association of Pathologist,

       June, 2006, Toronto, Ontario, Canada.


4)   Synchronous adrenocrtical and renal cell carcinoma: A rare association

  • Presentation at annual meeting of Canadian Association of Pathologist, June, 2006, Toronto, Ontario, Canada.
  • Prashant Jani, D.El-demallawy, The Canadian Journal of Urology, 2007 Jan;56(11):933-50.


5)   Value of CD 138 in normal and Pathological endometrium

  • Poster presentation at  Annual meeting of Canadian Association of Pathologist,

     June, 2006, Toronto, Ontario, Canada.


6)   Application of immunohistochemistry in classification of ovarian tumors

  • Poster presentation at American Society of Clinical pathology,Oct.2004 San Antonio, USA


7) An approach to duodenal biopsies. Review article.

  • S.Serra, P.Jani J Clin Pathol. 2006 Nov;59(11):1133-50. 2006

8)   Massive Bone Marrow Involvement by Alveolar Rhabdomyosarcoma with an

      Unusual Histologic Pattern and an Unknown Primary Site: A case Report with  

      Morphologic, Immunohistochemical, Ultrastructural, and Cytogenetic Studies

  • Prashant Jani, Charles Ye, Nov.2007,Journal of Clinical pathology.


9) An unusual composite pilomatrix carcinoma with intralesional melanocytes: differential

    diagnosis, immunohistochemical evaluation, and review of the literature. Jani Prashant; Chetty Runjan; Ghazarian Danny M.  The American Journal of dermatopathology  2008;30(2):174-7.


10) Comparative analysis of CD 56, calretinin, and inhibin immunohistochemical staining in the diagnosis of ovarian granulosa cell tumors. 

  • Poster presentation-Unites states and Canadian Academyof Pathology, 2008,  Denver,USA


11)  Prognostic Relevance of 6q Deletion in Waldenström Macroglobulinemia: A Multi-Center Study ; Clinical Lymphoma & Myeloma March 2009


12 ) Long-term Outcomes of Hypofractionation Versus Conventional Radiation Therapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ of the Breast International journal of radiation oncology, biology, physics (Impact Factor: 4.59). 01/2014; DOI: 10.1016/j.ijrobp.2014.07.026


13) Age at diagnosis predicts local recurrence in women treated with breast-conserving surgery and postoperative radiation therapy for ductal carcinoma in situ: a population-based outcomes analysis. Current Oncology (Impact Factor: 1.63). 02/2014; 21(1):e96-e104. DOI: 10.3747/co.21.1604


14) Impact of Boost Radiation in the Treatment of Ductal Carcinoma In Situ: A Population-Based Analysis. International journal of radiation oncology, biology, physics (Impact Factor: 4.59). 07/2013; 86(3):491-497. DOI: 10.1016/j.ijrobp.2013.02.031


15) Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis. Breast Cancer Research and Treatment (Impact Factor: 4.47). 03/2013; DOI: 10.1007/s10549-013-2455-8


1)   Role of Pathologist in management of breast Cancer- Dec.2006
Faculty and Course coordinator,Practicing pathologist association meeting, ,B.J Medical College, University of Pune, Maharashtra, India.
2)  Her2/neu and Breast Cancer: May 2008
Faculty , Northern Ontario Cancer Research Foundation meeting Ontario, Canada.
3)  Cancer Pathology Course : Jan.2007 and 2008
 Faculty Lakehead University,Thunder Bay,Ontario,Canada,.
4) Surgical pathology CME –Feb.2009
course co-ordinator and faculty at B.J.Medical College and Sasson Genreal hospitals, Pune, India.
5)  Course Co-ordinator -International CME in Oncopathology- Jan. 2010

Course Co-ordinator -International CME in Oncopathology- Jan. 2011

Course Co-ordinator -International CME in Oncopathology- Jan. 2012-2018

Seminar – Cancer Biology 5th Jan.2011 at Lakehead University, Thunder Bay, Ontario, Canada. 

Seminar -“Colorectal Cancer- guidelines for margin and lymph node dissection.” 19th Jan.2011 at B.J.Medical College Pune, India. 

Seminar-“Role of Immunohistochemistry in Breast Pathology” 20th Jan. 2011 at Bharati Vidhyapeeth Medical College, Pune, India. 

11) Course Director-
Surgical Pathology Update, Jan 26th 2011 at Ahmedabad Medical Association, Gujarat, India. 

Seminar – “ Work up of Carcinoma of Unknown Primary”- 15th Feb.2011 at Bharati Vidhyapeeth, Pune, India. 

Seminar – “Her2/neu and Breast Cancer” , May 21, 2011, Teleconference with University of Texas Health Science Center at San Antonio, USA. 

  • College of Americal Pathologist (CAP)
  • American Society of Clinical Pathology.
  • College of Physicians and Surgeons of Canada.
  • Ontario Medical Association.(OMA)
  • United States and Canadian Academy Of   Pathology(USCAP)

  Today, there have been 3 visitors (22 hits) on this page!  
=> Do you also want a homepage for free? Then click here! <=